You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression

 

Online download statistics by month:

Online download statistics by month: February 2021 to August 2025

AbstractFullPdf
Feb 2021806806217
Mar 202131931990
Apr 202111211262
May 202112012049
Jun 202110210239
Jul 2021969633
Aug 202111311332
Sep 2021828245
Oct 2021818142
Nov 2021888855
Dec 2021959539
Jan 2022828429
Feb 2022545626
Mar 2022868751
Apr 2022515330
May 2022738146
Jun 2022484832
Jul 2022636635
Aug 2022747434
Sep 2022505346
Oct 2022898977
Nov 2022575734
Dec 2022292918
Jan 2023404337
Feb 2023676728
Mar 2023323320
Apr 2023212126
May 2023323228
Jun 2023373820
Jul 2023303025
Aug 2023242420
Sep 2023181813
Oct 2023393927
Nov 2023515127
Dec 2023494938
Jan 2024373830
Feb 2024393929
Mar 2024545461
Apr 2024525347
May 2024383822
Jun 2024545438
Jul 2024838442
Aug 2024373828
Sep 20244041202
Oct 2024565638
Nov 2024626329
Dec 2024616235
Jan 2025686844
Feb 2025545435
Mar 2025636348
Apr 2025898934
May 2025666744
Jun 2025323230
Jul 2025110
Aug 2025110
Total419742312306